Against diabetes and liver steatosis
A breakthrough drug for the treatment of type I and type II diabetes has been created
Svetlana Maslova, Hi-tech+
Treatment with an experimental drug coped with all the main manifestations of the disease in mice, did not cause side effects and, from the point of view of glucose control, was better than the two most commonly prescribed drugs today. In addition to diabetes, the new therapy may be effective for non-alcoholic fatty liver disease.
The experimental drug SRI-37330 is a small molecule that has shown strong antidiabetic properties on human and mouse cell cultures and mouse models of type 1 and type 2 diabetes. SRI-37330 has a positive effect on pancreatic islet cells that produce the hormones insulin and glucagon, as well as on the liver, experiments have shown. The findings of the work are published on the website of the University of Alabama at Birmingham (Novel diabetes drug candidate shows promising properties in human islets and mouse models).
Article by Thielen et al. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action is published in the journal Cell Metabolism – VM.
The drug was administered orally. The therapy improved four symptoms of the disease at once: hyperglycemia, hyperglucagonemia, excessive production of glucose by the liver, as well as the accumulation of fat in the liver.
For example, adding SRI-37330 to the drinking water of mice with type 2 diabetes and obesity for several days normalized blood glucose levels. In the model of type I diabetes, treatment protected against the development of the disease.
SRI-37330 has achieved better blood glucose control than the two leading diabetes drugs, metformin and empagliflozin.
"Although the safety and efficacy of SRI-37330 for humans has yet to be determined, the treatment is very effective for human pancreatic islet cells, and is also well tolerated in rodents," the authors emphasized. In their opinion, the treatment can be effective for people with type I and type II diabetes, both with obesity and weight deficiency, as well as for the treatment of non-alcoholic fatty liver disease, which is very often suffered by people with obesity and diabetes.
Portal "Eternal youth" http://vechnayamolodost.ru